Organization | University of Western Australia

University of Western Australia Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4

Founded: Perth Australia (1911)

Organization Overview

First Clinical Trial

1988

NCT00003093

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2022

Timeline

NOW

Now

Alternative names

Department of Gastroenterology, Fremantle Hospital | Faculty of Health and Medical Sciences University of Western Australia | Fremantle Hospital | Fremantle Hospital and Health Service | Fremantle Hospital, WA, Australia | Head of Department, Medical Oncology, Sir Charles Gairdner Hospital | Lions Eye Institute, The University of Western Australia | Perth Medical School | Princess Margaret Hospital for Children | Princess Margaret Hospital for Children (Australia) | Princess Margaret Hospital for Children, Australia | Royal Perth Hospital | Royal Perth Hospital / University of Western Australia | School of Medicine and Pharmacology, Royal Perth Hospital | School of Medicine and Pharmacology, University of Western Australia, Fremantle Hospital | School of Paediatrics and Child Health, University of Western Australia | School pf Medicine and Pharmacology, Royal Perth Hospital. | Sir Charles Gairdner Hospital | Sir Charles Gairdner Hospital - Nedlands | Telethon Kids Institute, University of Western Australia, Perth, Australia | The University of Western Australia | University Department of Medicine, Royal Perth Hospital, University of Western Australia | University of Western Australia and Royal Perth Hospital | University of Western Australia, Fremantle Hospital | William Pomat | Zohaib Akram

Active Ingredients

Drugs in Phase 4 Trials (43)

amlodipine (norvasc) (1 trial)

artemether (1 trial)

atorvastatin (lipitor) (3 trials)

attenuated measles vaccine - Edmonston strain (rubeovax) (1 trial)

azithromycin (zithromax) (2 trials)

bacille calmette-guerin (2 trials)

bifidobacterium breve (1 trial)

bifidobacterium infantis (1 trial)

bifidobacterium longum (1 trial)

bromhexine (1 trial)

cyproheptadine (periactin) (1 trial)

dexmedetomidine (precedex) (3 trials)

dextrothyroxine (choloxin) (1 trial)

empagliflozin (jardiance) (1 trial)

fenofibrate (fenoglide) (2 trials)

fish oil (Omegavan) (3 trials)

fluvoxamine (luvox) (1 trial)

gw-501516 (Cardarine) (1 trial)

Lactobacillus acidophilus (1 trial)

lactobacillus casei (1 trial)

lactobacillus delbrueckii (1 trial)

lactobacillus plantarum (1 trial)

levobupivacaine (chirocaine) (1 trial)

lidocaine (xylocaine) (1 trial)

lumefantrine (Coartem) (1 trial)

moxonidine (2 trials)

niclosamide (nicloside) (1 trial)

olive (1 trial)

piperaquine (1 trial)

primaquine (2 trials)

pyrimethamine (daraprim) (2 trials)

remifentanil (ultiva) (2 trials)

ropivacaine (naropin) (1 trial)

sodium phosphate (1 trial)

sodium picosulfate (Preopik) (1 trial)

streptococcus salivarius (1 trial)

sulfadoxine (2 trials)

tacrolimus (prograf) (1 trial)

tibolone (xyvion) (1 trial)

triamcinolone (kenalog) (2 trials)

verapamil (calan) (1 trial)

vitamin d3 (1 trial)

vsl #3 (1 trial)

Drugs in Phase 3 Trials (35)

10-valent Pneumococcal Conjugate Vaccine (Pneumosil) (1 trial)

autologous plasma (1 trial)

carboplatin (paraplatin) (2 trials)

chloroquine (1 trial)

cisplatin (platinol) (1 trial)

cyclophosphamide (cytoxan) (1 trial)

cytarabine (cytosar-u) (1 trial)

dacomitinib (vizimpro) (1 trial)

doxorubicin (Doxil) (1 trial)

durvalumab (imfinzi) (1 trial)

esomeprazole (nexium) (1 trial)

etoposide (vepesid) (2 trials)

gemcitabine (gemzar) (1 trial)

hydroxyethyl starch (voluven) (1 trial)

idarubicin (idamycin) (1 trial)

ifosfamide (ifex) (1 trial)

leucovorin (1 trial)

mesna (mesnex) (1 trial)

metoclopramide (reglan) (1 trial)

midodrine (proamatine) (1 trial)

minocycline (minocin) (1 trial)

naltrexone (revia) (1 trial)

paclitaxel (taxol) (2 trials)

pegaspargase (oncaspar) (1 trial)

peginterferon beta-1a (Plegridy) (1 trial)

pneumococcal 13-valent conjugate vaccine (prevnar 13) (2 trials)

quinapril (accupril) (1 trial)

rosuvastatin (crestor) (1 trial)

sargramostim (leukine) (1 trial)

sevoflurane (ultane) (1 trial)

sodium chloride (2 trials)

temozolomide (temodar) (1 trial)

tioguanine (Lanvis) (1 trial)

vincristine (oncovin) (1 trial)

Drugs in Phase 2 Trials (21)

23-valent pneumococcal polysaccharide vaccine (pneumovax-23) (1 trial)

acetylcysteine (mucomyst) (1 trial)

afuresertib (1 trial)

albuterol (proventil) (1 trial)

autologous mesenchymal stem cells (2 trials)

bilastine (1 trial)

brostallicin (1 trial)

budesonide (rhinocort) (1 trial)

dabrafenib (tafinlar) (1 trial)

dacarbazine (dtic-dome) (1 trial)

Filgrastim (neupogen) (1 trial)

inactivated influenza vaccine (2 trials)

ipratropium (atrovent) (1 trial)

magnesium oxide (1 trial)

mannitol (Osmitrol) (1 trial)

nitazoxanide (Alinia) (1 trial)

pi-88 (1 trial)

pneumococcal 7-valent conjugate vaccine (Prevnar) (1 trial)

rituximab (rituxan) (1 trial)

trametinib (mekinist) (1 trial)

Drugs in Phase 1 Trials (5)

alteplase (Activase) (1 trial)

dornase alfa (pulmozyme) (1 trial)

oxi4503 (1 trial)

pg545 (2 trials)

volitinib (1 trial)

Drugs in Other Trials (6)

folic acid (1 trial)

hepatitis b vaccine (recombinant) (Recombivax) (1 trial)

hydroxocobalamin (cyanokit) (1 trial)

misoprostol (cytotec) (2 trials)

oxytocin (syntocinon) (1 trial)

pyridoxine (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Anemia (Phase 3)

Autonomic Nervous System Diseases (Phase 4)

Bacteremia (Phase 3)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Carcinoma, Ovarian Epithelial (Phase 2)

Carcinoma, Transitional Cell (Phase 3)

Cardiovascular Diseases (Phase 4)

Central Nervous System Neoplasms (Phase 3)

Colitis (Phase 4)

Colitis, Ulcerative (Phase 4)

Communicable Diseases (Phase 2)

Conjunctivitis (Phase 2)

Conjunctivitis, Allergic (Phase 2)

Coronavirus Infections (Phase 3)

Critical Illness (Phase 3)

Crohn Disease (Phase 4)

Delirium (Phase 3)

Diabetes Mellitus (Phase 3)

Diabetes Mellitus, Type 1 (Phase 3)

Dyslipidemias (Phase 3)

Edema (Phase 3)

Gastroenteritis (Phase 2)

Gastroesophageal Reflux (Phase 3)

Gastrointestinal Stromal Tumors (Phase 2)

Graft vs Host Disease (Phase 2)

Hypertension (Phase 4)

Hypertriglyceridemia (Phase 4)

Hypotension (Phase 3)

Hypothyroidism (Phase 4)

Infections (Phase 3)

Inflammation (Phase 4)

Influenza, Human (Phase 2)

Insulin Resistance (Phase 3)

Ischemia (Phase 4)

Keloid (Phase 4)

Kidney Diseases (Phase 4)

Kidney Failure, Chronic (Phase 4)

Kidney Neoplasms (Phase 3)

Leukemia (Phase 3)

Leukemia, Lymphoid (Phase 3)

Lipid Metabolism Disorders (Phase 4)

Liver Neoplasms (Phase 1)

Lung Diseases (Phase 2)

Lung Diseases, Obstructive (Phase 2)

Lung Neoplasms (Phase 3)

Macular Edema (Phase 3)

Malaria (Phase 4)

Malaria, Falciparum (Phase 4)

Melanoma (Phase 2)

Meningitis (Phase 3)

Mesothelioma (Phase 3)

Metabolic Syndrome (Phase 4)

Mucositis (Phase 4)

Muscle Cramp (Phase 2)

Mycobacterium Infections (Phase 2)

Mycobacterium Infections, Nontuberculous (Phase 2)

Neoplasm Metastasis (Phase 1)

Neoplasms (Phase 1)

Nervous System Diseases (Phase 4)

Nervous System Neoplasms (Phase 3)

Neuroblastoma (Phase 3)

Neurotoxicity Syndromes (Phase 3)

Obesity (Phase 4)

Otitis Media (Phase 3)

Ovarian Neoplasms (Phase 2)

Peritonitis (Phase 1)

Pneumonia (Phase 3)

Polycystic Ovary Syndrome (Phase 4)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 3)

Proctitis (Phase 4)

Recurrence (Phase 4)

Renal Insufficiency, Chronic (Phase 2)

Reperfusion Injury (Phase 4)

Sarcoma (Phase 2)

Severe Acute Respiratory Syndrome (Phase 3)

Sexually Transmitted Diseases (Phase 3)

Spasm (Phase 2)

Syndrome (Phase 4)

Ulcer (Phase 4)

Ureteral Neoplasms (Phase 3)

Urethral Neoplasms (Phase 3)

Urinary Bladder Neoplasms (Phase 3)

Urticaria (Phase 2)

Overview

Highest Phase: Phase 4
# of Trials: 69
# of Trial APIs: 110